UBS O'Connor’s ARS Pharmaceuticals SPRY Stock Holding History

UBS O'Connor’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-149,915	Closed	-$976K	–	638
2023 Q1	$976K	Buy	+149,915	New	+$1.15M	0.02%	406

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's SPRY Position: Q2 2023 in Review

UBS O'Connor sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 149,915 shares — an estimated $976K sold.

UBS O'Connor first reported a position in SPRY in Q1 2023 and held it in 1 quarter. The position peaked at $976K in Q1 2023. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

UBS O'Connor reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
UBS O'Connor sold 149,915 ARS Pharmaceuticals shares in Q2 2023, an estimated $976K.
UBS O'Connor first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 1 quarter.
UBS O'Connor's ARS Pharmaceuticals position peaked at $976K in Q1 2023.
92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.